Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 4096 AL 4110

The silent invaders: Biofilms in neurological, cardiovascular, and metabolic diseases

Kumar V, Tyagi A.

Life Sci. 2025 Oct 15;379:123886. doi: 10.1016/j.lfs.2025.123886. Epub 2025 Jul 30.

Metabolomics: Potential non-protein biomarker candidates of Parkinson's disease

Kaleta M, Gonzalez G, Hényková E, Menšíková K, Koníčková D, Kaňovský P.

Neurosci Biobehav Rev. 2025 Sep;176:106310. doi: 10.1016/j.neubiorev.2025.106310. Epub 2025 Jul 30.

Broadening perspectives on hypoglycemia diagnosis in non-diabetic patients

Rodríguez Jiménez B, Jiménez Varo I, Ortega Ortega FF, Méndez Muros M, Sánchez Fernández F, Martínez-Brocca MA.

Endocrinol Diabetes Nutr (Engl Ed). 2025 Aug-Sep;72(7):501599. doi: 10.1016/j.endien.2025.501599.

Teen Presentation of Dyssynchronous Left Ventricular Cardiomyopathy Secondary to Wolff-Parkinson-White Syndrome and Right-Sided Septal Pathway

Shah PV, Patel DA, Ganigara M, Earing MG.

JACC Case Rep. 2025 Jul 30;30(21):104400. doi: 10.1016/j.jaccas.2025.104400.

Reply to the commentary on Defining 'OFF' time in device-aided therapy criteria for Parkinson's disease: Gaps and opportunities

Bhidayasiri R, Lean PL, Chaudhuri KR.

Parkinsonism Relat Disord. 2025 Nov;140:107979. doi: 10.1016/j.parkreldis.2025.107979. Epub 2025 Jul 28.

Neurodegeneration in Parkinson's disease: are we looking at the right spot?

Rocha GS, Freire MAM, Falcao D, Outeiro TF, Lima RR, Santos JR.

Mol Brain. 2025 Aug 1;18(1):68. doi: 10.1186/s13041-025-01218-6.

Next-generation CRISPR gene editing tools in the precision treatment of Alzheimer's and Parkinson's disease

Meshram HK, Gupta SK, Gupta A, Nagori K, Ajazuddin.

Ageing Res Rev. 2025 Sep;111:102851. doi: 10.1016/j.arr.2025.102851. Epub 2025 Aug 5.

Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson's disease and ageing research

Bezard E, Anderson RM, Badin RA, Bergman H, Boehringer A, Borgognon S, Emborg ME, Kordower JH, Li JY, Martel AC, Metzger JM, Smith Y, Takada M, Takahashi J, Takahashi R, Dehay B.

NPJ Parkinsons Dis. 2025 Aug 2;11(1):227. doi: 10.1038/s41531-025-01088-8.

Targeting pantothenate kinases in human diseases: Biochemistry and pharmacotherapy

Zhang X, Zhang B, Li X, Qiu F, Zhang Q, Kang N.

Biochem Pharmacol. 2025 Dec;242(Pt 2):117207. doi: 10.1016/j.bcp.2025.117207. Epub 2025 Aug 5.

Low frequency magnetic field exposure and neurodegenerative disease: systematic review of animal studies

Stam R.

Electromagn Biol Med. 2025;44(4):566-580. doi: 10.1080/15368378.2025.2540435. Epub 2025 Aug 3.

Neuromodulation influences T lymphocyte calcium signaling and alpha synuclein clearance: implications for Parkinson's disease

Ross A, Prowse N, Zhang H, Hayley S, Sun H.

Front Cell Neurosci. 2025 Jul 18;19:1627305. doi: 10.3389/fncel.2025.1627305. eCollection 2025.

Fixing a Shaky Video to Remotely Program Deep Brain Stimulation

Justich MB, Boogers A, Lozano AM, Fasano A.

Tremor Other Hyperkinet Mov (N Y). 2025 Jul 28;15:33. doi: 10.5334/tohm.963. eCollection 2025.

Efficacy and safety of oral amantadine in Parkinson's disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials

Rujirussawarawong S, Aungsumart S, Kasemsuk C, Limotai N.

BMJ Neurol Open. 2025 Jun 15;7(1):e001115. doi: 10.1136/bmjno-2025-001115. eCollection 2025.

Motor symptoms of Parkinson's disease: critical markers for early AI-assisted diagnosis

Yang N, Liu J, Sun D, Ding J, Sun L, Qi X, Yan W.

Front Aging Neurosci. 2025 Jul 18;17:1602426. doi: 10.3389/fnagi.2025.1602426. eCollection 2025.

Neuropsychiatric disorders in Parkinson's disease

Heim B, Djamshidian A.

Ther Adv Neurol Disord. 2025 Jul 28;18:17562864251356062. doi: 10.1177/17562864251356062. eCollection 2025.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias